1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: Potency is supported by X-ray crystallography of two leads

Bioorg Med Chem. 2017 Sep 1;25(17):4560-4565. doi: 10.1016/j.bmc.2017.06.054. Epub 2017 Jul 11.

Abstract

Two lead 1,3-oxazole-based carbonic anhydrase inhibitors (CAIs) earlier identified as selective, picomolar inhibitors of hCA II (a cytosolic target for treatment of glaucoma) have been investigated further. Firstly, they were found to be conveniently synthesized on multigram scale, which enables further development. These compounds were found to be comparable in efficacy to dorzolamide eye drops when applied in the eye drop form as well. Finally, the reasons for unusually high potency of these compounds became understood from their high-resolution X-ray crystallography structures. These data significantly expand our understanding of heterocycle-based primary sulfonamides, many of which have recently emerged from our labs - particularly, from the corneal permeability standpoint.

Keywords: Carbonic anhydrase inhibitors; Isoform selectivity; Multigram synthesis; Ocular hypertension; Picomolar inhibition; Primary sulfonamide; X-ray crystallography.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Binding Sites
  • Carbonic Anhydrase II / antagonists & inhibitors*
  • Carbonic Anhydrase II / metabolism
  • Carbonic Anhydrase Inhibitors / chemistry*
  • Carbonic Anhydrase Inhibitors / pharmacology
  • Carbonic Anhydrase Inhibitors / therapeutic use
  • Crystallography, X-Ray
  • Humans
  • Intraocular Pressure / drug effects
  • Male
  • Molecular Conformation
  • Molecular Dynamics Simulation
  • Ocular Hypertension / drug therapy
  • Oxazoles / chemistry*
  • Oxazoles / pharmacology
  • Oxazoles / therapeutic use
  • Protein Structure, Tertiary
  • Rabbits

Substances

  • Carbonic Anhydrase Inhibitors
  • Oxazoles
  • Carbonic Anhydrase II